(lp0
S"Genomic Health  Up 2.1% Since Earnings Report: Can It Continue? Nasdaq - 18 hours ago It has been about a month since the last earnings report for Genomic Health, Inc.GHDX . Shares have added about 2.1% in that time frame, outperforming the market.Genomic Health's Cancer Test Business Strong, Expenses High - Yahoo Finance"
p1
aS'Why Genomic Health Inc. Jumped Higher Today Motley Fool - Feb 15, 2017 Genomic Health delivered 8% more genetic tests in the fourth quarter than it did in Q4 2015. More importantly, product revenue rose even faster -- up 10% year over year -- as the company was able to get paid for more of its genetic cancer tests from ...Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results ... - PR Newswire '
p2
aS"Genomic Health, Inc.: Almost at Breakeven Motley Fool - Nov 3, 2016 2015, that validated the company's invasive breast cancer test and reaccelerated growth of the test. The number of prostate cancer tests delivered increased 6% year over year, which isn't that great for an up-and-coming test, but Genomic Health has a ..."
p3
aS"Genomic Health, Inc. Earnings: Waiting for  Reimbursement Motley Fool - May 11, 2016 Kim Popovits, Genomic Health's chairman, CEO, and president, hinted that there might be a backlog of prostate cancer tests that the company hasn't reported yet: &quot;We are only reporting tests delivered, so we're not reporting tests ordered but tests ..."
p4
aS"3 Things to Watch as Genomic Health, Inc. Releases Earnings Motley Fool - May 3, 2016 Revenue is important, but with not all of its tests being reimbursed, the number of tests performed is a better indicator of the company's long-term trajectory . Management guided for Genomic Health to ..."
p5
aS'Why Genomic Health, Inc. Earned a Higher Share Price Motley Fool - May 5, 2016 What: Genomic Health  is up 11% at 12 p.m. ET after reporting solid earnings following the bell yesterday. So what: Revenue increased 19% year over year while tests delivered increased 16%.'
p6
aS'Genomic Health, Inc. Pushes Toward Profitability Motley Fool - Aug 4, 2016 The company continues to guide for a net loss in the range of $12 million to $18 million, assuming it hits the mid-point of its revenue guidance.'
p7
aS"Genomic Health's Breast Recurrence Test Data Encouraging Zacks.com - Mar 21, 2017 Genomic Health, Inc.  , a leading molecular diagnostics company, recently presented results from 15 Oncotype DX Breast Recurrence Score studies.Wall Street Stories: Genomic Health, Inc. , Audentes Therapeutics ... - Benchmark MonitorNew Analyst Ratings On Genomic Health, Inc.  - NewsDen"
p8
aS"Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver ... PR Newswire  - Jul 7, 2016 REDWOOD CITY, Calif. and SAN DIEGO, July 7, 2016 /PRNewswire/ -- Genomic Health, Inc.  and Epic Sciences, Inc. today announced an exclusive agreement to commercialize Epic Sciences' novel AR-V7 liquid biopsy test in the United&nbsp;...Genomic Health to Market Epic Sciences' AR-V7 Liquid Biopsy Test - GenomeWeb"
p9
aS'Genomic Health to Present at the 35th Annual JP Morgan Healthcare Conference PR Newswire  - Sep 28, 2016 3, 2017 /PRNewswire/ -- Genomic Health, Inc.  today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis&nbsp;...'
p10
a.